Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
3 trials since 2013, 1 ongoing, by the sponsor of the products; see every authorized trial
A phase 2/3 trial of the efficacy and safety of bardoxolone methyl in patients with alport syndromeMay 31, 2017 · Ongoing · Bardoxolone (RTA-402)
An extended access program to assess long term safety of bardoxolone methyl in patients with pulmonary hypertension.Apr 18, 2017 · Closed · Bardoxolone (RTA-402)
A study of the efficacy and safety of bardoxolone methyl in patients with connective tissue disease-associated…Nov 16, 2016 · Closed · Bardoxolone (RTA-402)
Orphan designations (FDA)
6 designations since 1983, 0 approved for the designated use, matched by the sponsor's name; see all orphan designations
Bardoxolone methylTreatment of autosomal dominant polycystic kidney disease · Jun 3, 2019
OmaveloxoloneTreatment of stage IIb through IV malignant melanoma · Sep 5, 2017
Spellings are joined only when they reduce to the same name, or a reviewed source names the same company. Sharing an FDA establishment number (FEI) is not enough: contract sites make products for many firms. Facts marked AI were labelled by a language model from the firm's FDA names; everything else comes from FDA or Wikidata.